Literature DB >> 31351173

Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.

Fred Yeboah1, Tae-Eun Kim2, Anke Bill3, Ulf Dettmer4.   

Abstract

α-Synuclein (αS) and tau have a lot in common. Dyshomeostasis and aggregation of both proteins are central in the pathogenesis of neurodegenerative diseases: Parkinson's disease, dementia with Lewy bodies, multi-system atrophy and other 'synucleinopathies' in the case of αS; Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy and other 'tauopathies' in the case of tau. The aggregated states of αS and tau are found to be (hyper)phosphorylated, but the relevance of the phosphorylation in health or disease is not well understood. Both tau and αS are typically characterized as 'intrinsically disordered' proteins, while both engage in transient interactions with cellular components, thereby undergoing structural changes and context-specific folding. αS transiently binds to (synaptic) vesicles forming a membrane-induced amphipathic helix; tau transiently interacts with microtubules forming an 'extended structure'. The regulation and exact nature of the interactions are not fully understood. Here we review recent and previous insights into the dynamic, transient nature of αS and tau with regard to the mode of interaction with their targets, the dwell-time while bound, and the cis and trans factors underlying the frequent switching between bound and unbound states. These aspects are intimately linked to hypotheses on how subtle changes in the transient behaviors may trigger the earliest steps in the pathogenesis of the respective brain diseases. Based on a deeper understanding of transient αS and tau conformations in the cellular context, new therapeutic strategies may emerge, and it may become clearer why existing approaches have failed or how they could be optimized.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31351173      PMCID: PMC6834908          DOI: 10.1016/j.nbd.2019.104543

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  217 in total

Review 1.  α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.

Authors:  Sushil K Singh; Aloke Dutta; Gyan Modi
Journal:  Future Med Chem       Date:  2017-06-20       Impact factor: 3.808

2.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.

Authors:  K A Conway; J D Harper; P T Lansbury
Journal:  Biochemistry       Date:  2000-03-14       Impact factor: 3.162

3.  α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer.

Authors:  Bruno Fauvet; Martial K Mbefo; Mohamed-Bilal Fares; Carole Desobry; Sarah Michael; Mustafa T Ardah; Elpida Tsika; Philippe Coune; Michel Prudent; Niels Lion; David Eliezer; Darren J Moore; Bernard Schneider; Patrick Aebischer; Omar M El-Agnaf; Eliezer Masliah; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

4.  Phosphorylation affects the ability of tau protein to promote microtubule assembly.

Authors:  G Lindwall; R D Cole
Journal:  J Biol Chem       Date:  1984-04-25       Impact factor: 5.157

5.  alpha-Synuclein is phosphorylated in synucleinopathy lesions.

Authors:  Hideo Fujiwara; Masato Hasegawa; Naoshi Dohmae; Akiko Kawashima; Eliezer Masliah; Matthew S Goldberg; Jie Shen; Koji Takio; Takeshi Iwatsubo
Journal:  Nat Cell Biol       Date:  2002-02       Impact factor: 28.824

6.  Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

Authors:  Roman Rouzier; Radhika Rajan; Peter Wagner; Kenneth R Hess; David L Gold; James Stec; Mark Ayers; Jeffrey S Ross; Peter Zhang; Thomas A Buchholz; Henry Kuerer; Marjorie Green; Banu Arun; Gabriel N Hortobagyi; W Fraser Symmans; Lajos Pusztai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-24       Impact factor: 11.205

Review 7.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

8.  GAK rs1564282 and DGKQ rs11248060 increase the risk for Parkinson's disease in a Chinese population.

Authors:  Yong Ping Chen; Wei Song; Rui Huang; Ke Chen; Bi Zhao; Jianpeng Li; Yuan Yang; Hui-Fang Shang
Journal:  J Clin Neurosci       Date:  2013-04-23       Impact factor: 1.961

9.  Direct detection of alpha synuclein oligomers in vivo.

Authors:  Hemi Dimant; Suneil K Kalia; Lorraine V Kalia; Liya N Zhu; Laura Kibuuka; Darius Ebrahimi-Fakhari; Nikolaus R McFarland; Zhanyun Fan; Bradley T Hyman; Pamela J McLean
Journal:  Acta Neuropathol Commun       Date:  2013-05-09       Impact factor: 7.801

10.  Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Authors:  Gordon K Wilcock; Serge Gauthier; Giovanni B Frisoni; Jianping Jia; Jiri H Hardlund; Hans J Moebius; Peter Bentham; Karin A Kook; Bjoern O Schelter; Damon J Wischik; Charles S Davis; Roger T Staff; Vesna Vuksanovic; Trevor Ahearn; Luc Bracoud; Kohkan Shamsi; Ken Marek; John Seibyl; Gernot Riedel; John M D Storey; Charles R Harrington; Claude M Wischik
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more
  11 in total

Review 1.  Parkinson's disease: proteinopathy or lipidopathy?

Authors:  Saranna Fanning; Dennis Selkoe; Ulf Dettmer
Journal:  NPJ Parkinsons Dis       Date:  2020-01-03

2.  Crowded organelles, lipid accumulation, and abnormal membrane tubulation in cellular models of enhanced α-synuclein membrane interaction.

Authors:  Maria Ericsson; Victoria von Saucken; Andrew J Newman; Lena Doehr; Camilla Hoesch; Tae-Eun Kim; Ulf Dettmer
Journal:  Brain Res       Date:  2021-02-09       Impact factor: 3.252

3.  Maackiain Ameliorates 6-Hydroxydopamine and SNCA Pathologies by Modulating the PINK1/Parkin Pathway in Models of Parkinson's Disease in Caenorhabditis elegans and the SH-SY5Y Cell Line.

Authors:  Rong-Tzong Tsai; Chia-Wen Tsai; Shih-Ping Liu; Jia-Xin Gao; Yun-Hua Kuo; Pei-Min Chao; Huey-Shan Hung; Woei-Cherng Shyu; Shinn-Zong Lin; Ru-Huei Fu
Journal:  Int J Mol Sci       Date:  2020-06-23       Impact factor: 5.923

Review 4.  Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk.

Authors:  Rakez Kayed; Ulf Dettmer; Sylvain E Lesné
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

Review 5.  Challenges in Discovering Drugs That Target the Protein-Protein Interactions of Disordered Proteins.

Authors:  Judit Oláh; Tibor Szénási; Attila Lehotzky; Victor Norris; Judit Ovádi
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

Review 6.  Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations.

Authors:  Benjamin Gabriel Poulson; Kacper Szczepski; Joanna Izabela Lachowicz; Lukasz Jaremko; Abdul-Hamid Emwas; Mariusz Jaremko
Journal:  RSC Adv       Date:  2019-12-24       Impact factor: 4.036

Review 7.  Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer's Pathogenesis.

Authors:  Botond Penke; Mária Szűcs; Ferenc Bogár
Journal:  Molecules       Date:  2020-04-03       Impact factor: 4.411

Review 8.  Parkinson's disease: proteinopathy or lipidopathy?

Authors:  Saranna Fanning; Dennis Selkoe; Ulf Dettmer
Journal:  NPJ Parkinsons Dis       Date:  2020-01-03

9.  FMRP-PKA Activity Negative Feedback Regulates RNA Binding-Dependent Fibrillation in Brain Learning and Memory Circuitry.

Authors:  James C Sears; Kendal Broadie
Journal:  Cell Rep       Date:  2020-10-13       Impact factor: 9.423

10.  Excess membrane binding of monomeric alpha-, beta- and gamma-synuclein is invariably associated with inclusion formation and toxicity.

Authors:  Tae-Eun Kim; Andrew J Newman; Thibaut Imberdis; Lisa Brontesi; Arati Tripathi; Nagendran Ramalingam; Saranna Fanning; Dennis Selkoe; Ulf Dettmer
Journal:  Hum Mol Genet       Date:  2021-11-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.